 |
|
Lowering the Intensity of Oral Anticoagulant Therapy
Effects on the Risk of Hemorrhage and Thromboembolism
Marieke Torn, MD;
Felix J. M. van der Meer, MD, PhD;
Frits R. Rosendaal, MD, PhD
Arch Intern Med. 2004;164:668-673.
Background Oral anticoagulation is effective in the prevention of arterial thromboembolism. The major drawback of coumarin therapy is the increased risk of hemorrhage. Implementing the optimal intensity of oral anticoagulation, ie, the level at which thromboembolic events are prevented without introducing an excessive bleeding risk, is an important step to improve the safety of oral anticoagulant therapy.
Methods We observed all patients of the Leiden Anticoagulation Clinic who were treated because of a mechanical heart valve or atrial fibrillation between January 1, 1995, and January 1, 1998, or because of cerebral ischemia between January 1, 1994, and January 1, 1998. In 1996, at the halfway point of follow-up, the target intensity for patients with a mechanical heart valve was lowered from 4.0 (range, 3.6-4.8) to 3.5 (range, 3.0-4.0) international normalized ratio, and for atrial fibrillation and cerebral ischemia, from 3.5 (range, 3.0-4.5) to 3.0 (range, 2.5-3.5) international normalized ratio. We compared in-cidence rates of hemorrhage and thromboembolism before and after the introduction of lower target intensities.
Results Higher target treatments were given to 2341 patients (2863 patient-years) and lower target treatments to 2256 patients (2260 patient-years). After introduction of the lower target ranges, the overall incidence rate of major untoward events declined from 5.7 (95% confidence interval [CI], 4.9-6.7) to 3.6 (95% CI, 2.8-4.4) per 100 patient-years. The incidence of major bleeding fell from 3.6 (95% CI, 2.9-4.4) to 2.7 (95% CI, 2.1-3.5) and the incidence of major thromboembolism from 2.0 (95% CI, 1.5-2.5) to 0.8 (95% CI, 0.5-1.3) per 100 patient-years.
Conclusion Implementation of lower target intensities for coumarin therapy decreased the complication risk.
From the Departments of Hematology (Drs Torn, van der Meer, and Rosendaal) and Clinical Epidemiology (Dr Rosendaal), Leiden University Medical Center, and Leiden Anticoagulation Clinic (Dr van der Meer), Leiden, the Netherlands. The authors have no relevant financial interest in this article.
RELATED LETTER
Establishing an Optimal Therapeutic Range for Coumarins
Giuseppe Bellelli, Renzo Rozzini, and Marco Trabucchi
Arch Intern Med. 2004;164(20):2282.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Establishing an Optimal Therapeutic Range for Coumarins: Filling in the Gaps
Martin O'Donnell and Jack Hirsh
Arch Intern Med. 2004;164(6):588-590.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT
| FULL TEXT
Anticoagulants in heart disease: current status and perspectives
De Caterina et al.
Eur Heart J 2007;0:ehl492v1-34.
FULL TEXT
Avoiding Central Nervous System Bleeding During Antithrombotic Therapy: Recent Data and Ideas
Hart et al.
Stroke 2005;36:1588-1593.
ABSTRACT
| FULL TEXT
Risk of bleeding with long-term antithrombotic therapy in atrial fibrillation
Schulman and Beyth
Eur Heart J Suppl 2005;7:C34-C40.
ABSTRACT
| FULL TEXT
Establishing an Optimal Therapeutic Range for Coumarins
Bellelli et al.
Arch Intern Med 2004;164:2282-2282.
FULL TEXT
A Silent Killer--Often Preventable
Futterman and Lemberg
Am J Crit Care 2004;13:431-436.
FULL TEXT
Establishing an Optimal Therapeutic Range for Coumarins: Filling in the Gaps
O'Donnell and Hirsh
Arch Intern Med 2004;164:588-590.
FULL TEXT
|
